Cardiovascular Epidemiology Overview

Principles

Definition

Cardiovascular epidemiology is a specialized discipline within public health and clinical research concerned with the study of the distribution, patterns, and determinants of cardiovascular diseases and their risk factors in defined populations. It employs epidemiological methodologies to identify causal associations, analyze trends, evaluate the effectiveness of preventive measures and treatments at the population level, and inform public health policy and clinical guidelines aimed at reducing the incidence and impact of heart and vascular conditions globally.

Ontological type

Core Risk Factors

Prevention and Policy

Study Designs

Key developments

Key Figures

Lipid-Centered Risk Paradigm era

William B. Kannel [1] was a leading figure in cardiovascular epidemiology during the Lipid-Centered Risk Paradigm era, with affiliations at Harvard University [3] and the University of California, San Francisco [4]. His contributions included the Framingham study findings on incidence of coronary heart disease and lipoprotein cholesterol levels [5], the development of cardiovascular disease risk profiles [6], and the serum cholesterol, lipoproteins, and the risk of coronary heart disease paper [7], which together established dose–response links and lipid-centered risk tools for population prevention. Philip A. Wolf [2] was a prominent figure in this era associated with Harvard University [3] and the University of California, San Francisco [4]. His work included atrial fibrillation as an independent risk factor for stroke in the Framingham Study [8] and a probability of stroke: a risk profile from the Framingham Study [9], thereby expanding population risk assessment to include AF and stroke within the lipid-centered paradigm.

Imaging-Driven Risk Integration era

Wayne D. Rosamond [1], affiliated with Harvard University [3] and Johns Hopkins University [4] during this era, helped shape cardiovascular epidemiology within the Imaging-Driven Risk Integration period. His key contributions, reflected in the Heart Disease and Stroke Statistics—2006 Update [7], the Heart Disease and Stroke Statistics—2009 Update [6], and the Heart Disease and Stroke Statistics—2010 Update [5], provided standardized, comprehensive burden estimates and risk factor trends that advanced risk stratification in imaging-informed epidemiology. Paul D. Sorlie [2], affiliated with Harvard University [3] and Johns Hopkins University [4] during this era, contributed to the same statistical enterprise through these updates, strengthening cross-cohort comparability. By delivering consistent, multi-ethnic epidemiologic data and enabling the integration of imaging metrics with inflammatory and circulating biomarkers, these Heart Disease and Stroke Statistics—2006 Update [7], Heart Disease and Stroke Statistics—2009 Update [6], and Heart Disease and Stroke Statistics—2010 Update [5] supported refined, individualized risk estimates across populations in this era.

Genomic-Precision Risk Translation era

Paul Muntner[1] is a cardiovascular epidemiologist active in this era, with affiliations at the American College of Preventive Medicine[3] and Stanford University[4]. His key contributions in this era include leading Heart Disease and Stroke Statistics—2016 Update[8], the Heart Disease and Stroke Statistics—2019 Update[7], and contributing to the 2017 Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary[9], which advanced population-level risk stratification, surveillance, and prevention in the genomic-precision era. Emelia J. Benjamin[2] is a cardiovascular epidemiologist whose work is anchored in Harvard University[5] and the Massachusetts Institute of Technology[6] during this era. Her contributions in this era include integrating large-scale genomic, imaging, and biomarker data with traditional cohorts to refine risk prediction and translate genomic insights into population health guidance, as reflected in the Heart Disease and Stroke Statistics—2019 Update[7] and the Heart Disease and Stroke Statistics—2016 Update[8], and the 2017 Guideline Executive Summary[9].